MedPath

ong-term effects of dapagliflozin, a SGLT2 inhibitor, on glucose metabolism in patients with type 2 diabetes mellitus

Not Applicable
Recruiting
Conditions
type 2 diabetes mellitus
Registration Number
JPRN-UMIN000026042
Lead Sponsor
Kurume University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

Repeated urinary tract infection HbA1c < 7.0% BMI < 22

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
fasting blood glucose, HbA1c, urinary sugar
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath